Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.24.2.u1
Commitments and Contingencies (Details Narrative)
€ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Apr. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
EUR (€)
Nov. 30, 2022
USD ($)
Jan. 31, 2019
USD ($)
Jul. 31, 2012
USD ($)
Loss Contingencies [Line Items]                      
Payment to acquire in process research and development           $ 12,000 $ 273,250        
Discovery Collaboration Agreements [Member] | XOMA [Member]                      
Loss Contingencies [Line Items]                      
Milestone payments                     $ 3,800,000
Discovery Collaboration Agreements [Member] | XOMA [Member] | In Process Research and Development [Member]                      
Loss Contingencies [Line Items]                      
License fee $ 500,000     $ 0 $ 0 $ 0 0        
Cellca Agreement [Member]                      
Loss Contingencies [Line Items]                      
Description of milestone payments           The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised          
Cellca Agreement [Member] | Maximum [Member]                      
Loss Contingencies [Line Items]                      
Milestone payments                   $ 700,000  
The Cellca Agreement [Member]                      
Loss Contingencies [Line Items]                      
Milestone payments       600,000   $ 600,000          
The Cellca Agreement [Member] | Maximum [Member]                      
Loss Contingencies [Line Items]                      
Payment for annual license fee obligation       600,000   600,000          
The Cellca Agreement [Member] | Minimum [Member]                      
Loss Contingencies [Line Items]                      
Payment for annual license fee obligation       100,000   100,000          
The Cellca Agreement [Member] | In Process Research and Development [Member]                      
Loss Contingencies [Line Items]                      
License fees $ 100,000     0 0 0 0        
The Brink Agreement [Member]                      
Loss Contingencies [Line Items]                      
Payment of annual license fee                 $ 12,000    
Commercial product license fee payment obligation       100,000   100,000          
The Brink Agreement [Member] | In Process Research and Development [Member]                      
Loss Contingencies [Line Items]                      
License fee       0 0 12,000 12,000        
Development license fee payments       100,000   100,000          
InvivoGen Agreement [Member]                      
Loss Contingencies [Line Items]                      
Payment for annual license fee obligation       100,000   100,000   € 0.1      
License fees       0 0 0 0        
ProteoNic Agreement [Member]                      
Loss Contingencies [Line Items]                      
License fees   $ 24,600   0   0          
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member]                      
Loss Contingencies [Line Items]                      
Milestone payments     $ 1,000,000.0                
Payment to acquire in process research and development     $ 100,000                
Navigo Agreement [Member] | Navigo Proteins GmbH [Member] | Technology Service [Member] | Research and Development Expense [Member]                      
Loss Contingencies [Line Items]                      
Milestone payments       0 0 0 0        
License fees       $ 0 $ 200,000 $ 0 $ 300,000